Shwu‐Luan Lee

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation”.

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1086

N/A

0.385DataRank · unranked

12 citations

Edwin C.Y. Chow, Alexei Ionan, Haiyan Chen, Shwu‐Luan Lee, Vicky Hsu +10 more

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4525

N/A

0DataRank · unranked

25 citations

Xin Wang, Meng Li, Hongshan Li, Shwu‐Luan Lee, Nina Ni +9 more